A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-29

Study Completion Date

2023-02-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

NCT03329950

Melanoma Non-small Cell Lung Cancer Breast Cancer +23 more

COMPLETED PHASE1

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

NCT03099161

Neoplasm

TERMINATED PHASE1

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

NCT03240211

PTCL CTCL

ACTIVE_NOT_RECRUITING PHASE1

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

NCT04609579

Advanced Solid Tumor Advanced Lymphoma

TERMINATED PHASE1

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720

Non-Hodgkin Lymphoma

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma Cervical Carcinoma Pancreatic Carcinoma Triple Negative Breast Cancer Hepatocellular Carcinoma Urothelial Carcinoma Squamous Cell Carcinoma of the Head and Neck Nasopharyngeal Carcinoma Renal Cell Carcinoma Non-small Cell Lung Carcinoma Small Cell Lung Carcinoma Gastric or Gastroesophageal Junction Adenocarcinoma Advanced or Metastatic Solid Tumors Prostate Carcinoma Epithelial Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma Intrahepatic Cholangiocarcinoma Squamous Cell Anal Cancer Squamous Cell Penile Carcinoma Squamous Cell Vulvar Carcinoma Colorectal Carcinoma Endometrial Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Arm 1: XmAb®22841 Monotherapy

Group Type EXPERIMENTAL

XmAb®22841

Intervention Type BIOLOGICAL

Monoclonal bispecific antibody

Arm 2

Arm 2: Combination of XmAb®22841 and Pembrolizumab (Keytruda®)

Group Type EXPERIMENTAL

XmAb®22841

Intervention Type BIOLOGICAL

Monoclonal bispecific antibody

Pembrolizumab (Keytruda®)

Intervention Type BIOLOGICAL

FDA-approved humanized monoclonal antibody

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

XmAb®22841

Monoclonal bispecific antibody

Intervention Type BIOLOGICAL

Pembrolizumab (Keytruda®)

FDA-approved humanized monoclonal antibody

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

PART A (Dose Escalation Cohorts)

1. All subjects' cancer must have progressed after treatment with all available therapies that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment.
2. All subjects must have adequate archival tumor, or give consent to a fresh tumor biopsy.
3. Subjects have an ECOG performance status of 0-1.
4. Subjects in monotherapy and combination therapy cohorts must have histologically or cytologically confirmed advanced or metastatic solid tumors, including the following:

1. Melanoma
2. Cervical carcinoma
3. Pancreatic carcinoma
4. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (TNBC)
5. Hepatocellular carcinoma
6. Urothelial carcinoma
7. Squamous cell carcinoma of the head and neck (HNSCC)
8. Nasopharyngeal carcinoma (NPC)
9. Renal cell carcinoma
10. Colorectal carcinoma or endometrial carcinoma
11. Small cell lung carcinoma or NSCLC
12. Gastric or gastroesophageal junction adenocarcinoma
13. Prostate adenocarcinoma
14. Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
15. Intrahepatic cholangiocarcinoma
5. Subjects in the combination cohorts in Part A with XmAb22841 and pembrolizumab may have an advanced solid tumor that either:

* has progressed after treatment with all available therapies that are known to confer clinical benefit, or is intolerant or has refused standard treatment (as for the XmAb22841 monotherapy cohorts), or
* is of a tumor type for which pembrolizumab is an approved indication and has not previously been treated with an agent targeting PD1 or PDL1.

PART B (Dose Expansion Cohorts)

XmAb22841 Single Agent Cohort

1\. Must have histologically or cytologically confirmed advanced or metastatic solid tumor that has progressed after treatment with all available therapies that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. Eligible tumor types include the following:

1. Anti-PD1 refractory melanoma (or any uveal melanoma)
2. Anti-PD1 refractory NSCLC
3. Anti-PD1 refractory renal cell carcinoma (with clear cell component)
4. Anti-PD1 refractory urothelial carcinoma
5. Head and neck squamous cell carcinoma
6. Hepatocellular carcinoma
7. Gastric adenocarcinoma
8. Cervical carcinoma
9. Breast carcinoma that is estrogen receptor, progesterone receptor, and HER2 negative (TNBC)
10. Epithelial ovarian cancer
11. Nasopharyngeal carcinoma
12. Squamous cell anal carcinoma
13. Squamous cell penile carcinoma
14. Squamous cell vulvar carcinoma

XmAb22841 + Pembrolizumab Cohorts

1. Anti-PD-1 refractory melanoma (excluding uveal melanoma)
2. Anti-PD-1 naïve melanoma (excluding uveal melanoma)
3. Anti-PD-1 refractory NSCLC
4. Anti-PD1 naïve NSCLC

a. Must be PD-L1 high (TPS ≥ 50%), with no EGFR or ALK aberrations
5. Anti-PD1 naïve urothelial carcinoma

1. Must be PDL1 positive (CPS of ≥ 10), or ineligible for any platinum-containing chemotherapy regardless of PDL1 status; or
2. Had disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

Exclusion Criteria

1. Prior treatment with an investigational anti-LAG3 therapy.
2. Treatment with any CTLA4 antibody within 16 weeks of the start of study drug for Cohorts 1M, 2M, 3M, 1P, and 2P; within 8 weeks for Cohorts 4M, 5M, 3P, 4P and 4Pi; and within 3 weeks for Cohorts 6M, 7Mi, 7M, 5P, and 6P.
3. Systemic antineoplastic therapy, unconjugated antibody therapy within 4 weeks of the first dose of study treatment; or radiotherapy within 2 weeks of the first dose of study treatment; or small molecule kinase inhibitors within 6 elimination half-lives of the first dose of study treatment.
4. Have received prior therapy with an anti-PD1, anti-PDL1, or anti PDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA4, OX 40, CD137) AND were permanently discontinued from that treatment due to an irAE.
5. Failure to recover from any irAE from prior cancer therapy to Grade ≤ 1.
6. Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to Grade ≤ 2.
7. Active known or suspected autoimmune disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus; residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and non-steroidal anti-inflammatory drugs).
8. Receipt of an organ allograft.
9. Treatment with antibiotics within 14 days prior to first dose of study drug.
10. Participants with known HIV.
11. Participants with known chronic hepatitis B virus (HBV) infection treated for less than 3 months prior to study enrollment and/or with a detectable HBV viral load; or hepatitis C virus (HCV) infection that has been treated for less than 4 weeks prior to study enrollment and/or with a detectable HCV viral load; or active HBV/HCV coinfection.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Benjamin Thompson, MD, PhD

Role: STUDY_DIRECTOR

Xencor, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.